For example, published studies have shown very infrequent responses with imatinib in PDGFRA D842V-mutant GIST, with only 3% (two out of 59) of patients across studies achieving a partial response to this treatment [3, 13–16]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.